SCHEMBL4509737

SCHEMBL4509737

CCn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(Cc3ccc(F)c(F)c3)nc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.38
BRD4 O60885 1/20 0.36
BRD2 P25440 1/20 0.36
BRD3 Q15059 1/20 0.36
BRDT Q58F21 1/20 0.36
YTHDC1 Q96MU7 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
MAT2A P31153 1/20 0.36
TSHR P16473 4/20 0.35
LMNA P02545 2/20 0.35
XBP1 P17861 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 1/20 0.35
AOC3 Q16853 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MAPK1 P28482 1/20 0.34
HIF1A Q16665 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4525433 0.92 POLB (0.37) CNR1BRD4BRD2BRD3BRDT
SCHEMBL4524676 0.90 GAA (0.43) CNR1BRD4BRD2BRD3BRDT
SCHEMBL4520072 0.89 MAT2A (0.38) CNR1BRD4BRD2BRD3BRDT
SCHEMBL4521275 0.88 ALDH1A3 (0.44) CNR1YTHDC1HPGDMAT2ANPSR1
SCHEMBL4526092 0.87 YTHDC1 (0.45) CNR1BRD4BRD2BRD3BRDT
SCHEMBL4530785 0.86 MAT2A (0.38) CNR1YTHDC1GAAPKMHPGD
SCHEMBL4520999 0.85 NPC1 (0.44) CNR1BRD4BRD2BRD3BRDT
SCHEMBL4531049 0.85 HPGD (0.46) CNR1YTHDC1HPGDTSHRLMNA
SCHEMBL4524598 0.85 RXFP1 (0.40) YTHDC1GAAPKMHPGDMAT2A
SCHEMBL4522510 0.85 GSR (0.40) CNR1YTHDC1GAAPKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) BROWN REBECCA ELIZABETH 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) TRPV1, TRPV2, TRPV4 CNR1 18/4885BRD4 508/4885BRD2 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.